These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://haleemaleqm598339.blogsumer.com/38118632/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide